GLP-1 Weight Loss Drugs Reshape Global Healthcare as Demand Surges in 2025-2026

A New Era in Obesity Medicine

The meteoric rise of GLP-1 receptor agonists — a class of drugs originally developed to treat type 2 diabetes — has fundamentally altered how the medical community approaches obesity and metabolic disease. Medications such as semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) have generated unprecedented demand, reshaping pharmaceutical markets and straining healthcare supply chains heading into 2026.

Novo Nordisk and Eli Lilly, the two dominant manufacturers, have invested tens of billions of dollars in manufacturing expansion to meet global demand, yet shortages have persisted in multiple countries throughout 2025 and into the new year.

Beyond Weight Loss: Expanding Medical Evidence

Clinical research has continued to broaden the recognized benefits of GLP-1 drugs well beyond blood sugar control and weight reduction. The landmark SELECT trial, whose findings were widely discussed through 2024 and 2025, demonstrated that semaglutide significantly reduced the risk of major cardiovascular events in overweight and obese adults — a finding that prompted updated prescribing guidelines in multiple countries.

More recently, ongoing studies have explored potential benefits in areas including chronic kidney disease, metabolic-associated fatty liver disease (MAFLD), obstructive sleep apnea, and even certain neurological conditions. The FDA approved semaglutide for reducing cardiovascular risk in a specific patient population in 2024, a milestone that opened the door to broader insurance coverage in the United States.

Access and Affordability Remain Critical Barriers

Despite the clinical enthusiasm, access to GLP-1 medications remains deeply unequal. In the United States, monthly costs for branded versions frequently exceed $1,000 without insurance coverage, placing these drugs out of reach for many patients who could medically benefit. Medicare coverage for anti-obesity medications has been a long-debated policy issue, with advocates pushing Congress to pass legislation that would allow Medicare Part D to cover these treatments more broadly.

Globally, the picture is similarly complex. High-income nations have moved more aggressively to approve and fund these therapies, while lower- and middle-income countries face significant barriers related to both cost and supply. The World Health Organization and various public health bodies have called for greater attention to equitable access as obesity rates climb in developing regions.

Compounding Controversy and Regulatory Scrutiny

The surge in demand fueled a parallel market in compounded versions of semaglutide and tirzepatide, particularly in the United States. Compounding pharmacies, which are permitted to produce copies of drugs that are officially listed as in shortage, supplied millions of patients during peak shortage periods. However, the FDA has moved to wind down permissions for compounding these specific drugs as manufacturers certify their ability to meet demand, triggering legal challenges from compounding pharmacy associations and patient advocacy groups.

Regulators are also closely monitoring the long-term safety profile of these medications, including reports of rare but serious gastrointestinal complications and ongoing studies into thyroid cancer risk — an area flagged in preclinical research though not yet confirmed in large human trials.

What Comes Next

The next generation of weight-loss therapies is already advancing through clinical pipelines. Oral formulations of GLP-1 drugs, once-weekly and once-monthly injectable options, and combination therapies targeting multiple metabolic pathways are all in development or under regulatory review. Analysts project the global obesity drug market could exceed $130 billion annually within the next decade.

For healthcare systems worldwide, the challenge will be determining how to integrate these powerful but expensive therapies sustainably — balancing clinical evidence, cost-effectiveness, and equitable access in a rapidly evolving landscape.